PolyPid Wraps Up Phase 3 Enrollment For D-PLEX100, Eyes FDA Submission Following Q2 Top-Line Data

The Company anticipates reporting top-line results by the end of the second quarter of 2025. If the Phase 3 data are positive, PolyPid expects to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA"), leveraging the FDA's Fast Track and Breakthrough Therapy designations.